<DOC>
	<DOCNO>NCT01895712</DOCNO>
	<brief_summary>For majority Coronary Artery Disease ( CAD ) , treatment Percutaneous Transluminal Coronary Angioplasty ( PTCA ) provide high initial procedural success . However , medium long-term complication range rather immediate elastic recoil vessel contraction longer process like smooth muscle cell proliferation excessive production extra cellular matrix , thrombus formation atherosclerotic change like restenosis angiographic re-narrowing . The reported incidence restenosis PTCA range 30 % -50 % . Such rate recurrence serious economic consequence . Bare Metal Stents ( BMS ) , design address limitation PTCA , reduce angiographic clinical restenosis rate de novo lesion compare PTCA alone decrease need CABG . BMS substantially reduce incidence abrupt artery closure , restenosis still occur 20 % -40 % case , necessitate repeat procedure . The invention Drug Eluting Stents ( DES ) significantly improve principle BMS add antiproliferative drug ( directly immobilize stent surface release polymer matrix ) , inhibit neointimal hyperplasia . The introduction DES greatly reduce incidence restenosis result good safety profile compare BMS systemic drug administration . These advantage low cost compare surgical intervention make DES attractive option treat coronary artery disease . An interesting group analysis result diabetic patient . It conclude incidence nonocclusive occlusive restenosis higher diabetic subject stenting judge comparison historical control subject . Results implicate accelerate restenosis consequence diabetes cause increase mortality PCI diabetic patient . Therefore observational registry design clinical evaluation Orsiro LESS diabetic subject ( Diabetic patient type 1 2 ) require coronary revascularization Drug Eluting Stents ( DES ) . Results contribute collection clinical evidence clinical performance safety Orsiro Drug Eluting Stent System daily clinical practice .</brief_summary>
	<brief_title>BIOFLOW-III Israel Satellite Registry</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patients diabetes mellitus Type 1 2 Stable coronary patient moderatesevere symptomatic angina ( CCS ≥II ) evidence myocardial ischemia per non invasive test ( nuclear echo ) patient 'silent ' myocardial ischemia large ( e.g . &gt; 10 % myocardium ) territory myocardium jeopardy ( nuclear echo ) Subject sign informed consent Subject geographically stable willing participate follow assessment Subject ≥ 18 year age Subject sign inform consent Left main disease Complex bifurcations Ostial lesion Three vessel disease Large visible thrombus Heavy calcify lesion need atherectomy cut balloon dilatation Syntax Score ≥33 Active bleed Sepsis Chronic total Occlusion Bleeding tendency obviate dual anti platelet ( DAP ) intake one year Hb &lt; 11/Plts,100.000/WBC &lt; 4000 &gt; 11.00 Pregnant nursing subject plan pregnancy period 3 year follow index procedure . ( Female subject child bear potential must negative pregnancy test do within 28 day prior index procedure contraception must use participation trial ) Known hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel prasugrel ticlopidine , inclusive ) , sirolimus , poly ( Llactide ) poly ( DLlactide ) , cobalt , chromium , nickel , tungsten , acrylic fluoro polymer contrast sensitivity adequately premedicated . Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain Currently participate another study primary endpoint reach yet . Other medical illness ( e.g , cancer congestive heart failure ) Known history substance abuse ( alcohol , cocaine , heroin etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>International</keyword>
	<keyword>Multicenter</keyword>
	<keyword>Observational registry</keyword>
	<keyword>Orsiro Drug Eluting Stents ( DES )</keyword>
	<keyword>Stenting</keyword>
	<keyword>Treatment Coronary Artery Disease</keyword>
	<keyword>Coronary revascularization</keyword>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
	<keyword>Diabetes Mellitus Type 1</keyword>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Angina</keyword>
	<keyword>Subgroups</keyword>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Small vessel</keyword>
	<keyword>Chronic Total Occlusion</keyword>
</DOC>